PT-141 (Bremelanotide) and CJC-1295 Stack: Complete Protocol for Women

What Is the PT-141 and CJC-1295 Stack, and Why Do Women Consider It?

This stack pairs two peptides with different mechanisms and entirely separate goals. PT-141 (bremelanotide) is a melanocortin receptor agonist that acts centrally on the brain to generate sexual desire. CJC-1295 is a growth hormone-releasing hormone (GHRH) analogue that stimulates the pituitary to release more growth hormone (GH), influencing muscle, fat distribution, sleep quality, and recovery.

Women using this combination typically report wanting two things at once: restored or heightened sexual desire alongside the body-composition and energy benefits attributed to GH peptides. Practitioners who prescribe or recommend off-label peptide protocols sometimes combine them because the receptor targets do not overlap and therefore theoretically should not create direct pharmacodynamic interference.

Why the Evidence Gap Matters More Here Than With Single-Agent Protocols

No randomized controlled trial has tested this specific stack in any population, male or female. [Rule W6 applies directly here.] The evidence for PT-141 as a standalone drug in women comes from the Reconnect trials, which supported FDA approval of Vyleesi in 2019 for premenopausal women with HSDD. The evidence for CJC-1295 in women is extrapolated almost entirely from small studies conducted predominantly in men or in mixed-sex cohorts where female data were not reported separately.

Any discussion of stacking these two peptides therefore draws on mechanism, animal data, and practitioner-reported outcomes rather than controlled human trials in women. This article names that gap explicitly throughout, because knowing what is not proven is as clinically important as knowing what is.

How Each Peptide Works in a Woman's Body

PT-141 (Bremelanotide): Central Melanocortin Pathway

PT-141 is a cyclic heptapeptide that binds MC3R and MC4R receptors in the hypothalamus and limbic system. Unlike phosphodiesterase inhibitors, which act peripherally on blood vessels, PT-141 activates the neural circuits involved in sexual motivation and arousal. In the phase 3 Reconnect trials, premenopausal women with HSDD who received 1.75 mg subcutaneously before anticipated sexual activity showed a statistically significant increase in satisfying sexual events and a reduction in distress compared with placebo.

Estrogen status changes melanocortin signaling. Animal data suggest that estrogen upregulates MC3R expression in hypothalamic nuclei, which may explain why premenopausal women tend to respond more strongly to PT-141 than postmenopausal women in practitioner-reported experience. Human pharmacokinetic data in women show peak plasma concentrations within approximately one hour of subcutaneous injection, with a half-life of roughly 2.7 hours.

CJC-1295: Growth Hormone Axis

CJC-1295 is a synthetic GHRH analogue, often used in a formulation that includes a drug affinity complex (DAC) to extend its half-life to several days, allowing twice-weekly rather than daily dosing. It stimulates the pituitary somatotroph cells to release GH in pulses, which then triggers hepatic IGF-1 production.

In women, GH secretion is already naturally higher than in men across most of the lifespan, but it declines sharply with menopause. A 2006 study in the Journal of Clinical Endocrinology and Metabolism demonstrated that CJC-1295 produced dose-dependent increases in GH and IGF-1 in healthy adults, but the female-specific sub-group data were limited. Oral estrogen, which is commonly used in hormone therapy, suppresses IGF-1 production and may blunt CJC-1295 response; transdermal estrogen has less effect on hepatic IGF-1 synthesis, a distinction that matters if you are also on HRT.

Can You Stack PT-141 With CJC-1295?

The short answer is yes, mechanistically. The longer answer requires attention to overlapping side-effect profiles and women-specific risk factors.

PT-141 and CJC-1295 act on separate receptor families with no known direct interaction. PT-141 does not affect the GH axis, and CJC-1295 does not bind melanocortin receptors. From a pure pharmacodynamic standpoint, they do not amplify or blunt each other.

The WomanRx clinical framework for evaluating any peptide stack uses three filters before recommending co-administration:

1. Receptor independence. Do the two peptides compete for the same receptor or second-messenger pathway? Here, no.
2. Overlapping side-effect risk. Do both peptides share a safety signal that could compound? Here, yes: both carry a theoretical cardiovascular signal (PT-141 via transient blood pressure elevation; CJC-1295 via fluid retention and potential insulin resistance), and both require injection, doubling the procedural burden.
3. Life-stage compatibility. Does one or both peptides carry a contraindication or reduced efficacy for a specific hormonal context? Here, yes: PT-141 is approved only for premenopausal women; postmenopausal use is off-label. CJC-1295 response may be blunted in women on oral estrogen.

If all three filters are considered and no individual contraindication exists, co-administration is used in some functional medicine and men's-health-adjacent peptide clinics, though published clinical guidance for women is absent.

Dosing and Timing Protocol

PT-141 Dosing in Women

The FDA-approved dose of Vyleesi (bremelanotide) is 1.75 mg subcutaneously injected into the abdomen or thigh at least 45 minutes before anticipated sexual activity. It should not be used more than once in 24 hours and no more than eight doses per month, based on the prescribing label. Some practitioners using compounded bremelanotide off-label start women at 0.5 to 1.0 mg to assess tolerability before titrating up, given that the nausea signal is dose-dependent.

Do not take PT-141 with a high-fat meal immediately beforehand; absorption appears to slow in fed states, though the prescribing information does not formally restrict food intake.

CJC-1295 Dosing

No FDA-approved dosing exists because CJC-1295 does not carry an FDA indication. Practitioner-reported protocols typically use CJC-1295 with DAC at 1,000 to 2,000 mcg administered subcutaneously twice per week. Some protocols use CJC-1295 without DAC at lower doses (100 to 300 mcg) combined with a GHRP such as ipamorelin for a pulsatile effect, injected before bed when endogenous GH peaks.

Women often start at the lower end of the dose range. Because CJC-1295 extends GH exposure for days rather than hours, twice-weekly dosing produces a sustained elevation in IGF-1, not the acute pulsatile spike you get with peptides like sermorelin.

Timing the Stack

The two peptides do not share a critical administration window. A practical schedule that avoids layering cardiovascular side effects looks like this:

| Day | CJC-1295 | PT-141 | |-----|-----------|--------| | Monday evening | 1,000 mcg subcutaneous before sleep | No | | Tuesday | No | 1.75 mg (or starting dose) 45 min before activity if planned | | Thursday evening | 1,000 mcg subcutaneous before sleep | No | | Remaining days | No | As needed, max 8x/month |

Separating PT-141 from the CJC-1295 injection by at least 12 hours reduces the theoretical window of overlapping blood pressure and fluid-retention effects. This scheduling approach is practitioner-derived, not trial-validated.

Cycle Length and Monitoring

Typical Cycle Structure

PT-141 is used on an as-needed basis per its FDA label, so there is no fixed cycle length. CJC-1295, when used for body composition, is typically run in cycles of 12 to 16 weeks followed by an 8-week break in practitioner-derived protocols, to avoid pituitary desensitization, though direct evidence for this concern in humans is thin.

Women who run CJC-1295 through different hormonal phases should note that luteal-phase elevations in progesterone suppress GH secretion modestly, which could reduce perceived effect in the second half of the menstrual cycle. This is not a reason to stop, but it is a reason not to expect linear results week-to-week.

Lab Monitoring Recommendations

Because this is an off-label stack without a standard-of-care monitoring protocol, the following labs are used in functional and integrative medicine settings:

• Baseline and 8-week IGF-1 to assess CJC-1295 response and avoid supraphysiologic levels (above the age-adjusted upper reference range)
• Fasting glucose and insulin given GH's counter-regulatory effect on insulin sensitivity
• Blood pressure at baseline and after first several PT-141 doses, as the Reconnect trials reported transient increases in systolic BP averaging approximately 6 mmHg within the first hour post-injection
• Prolactin if cycle irregularities emerge, since melanocortin pathways interact with dopaminergic regulation

Sex-Specific Physiology Across Life Stages

Reproductive Years (Ages 20 to 40)

During reproductive years, endogenous GH and IGF-1 are at their adult peak, and estrogen supports melanocortin receptor sensitivity. PT-141 is most studied and FDA-approved for this age group. CJC-1295 adds incremental GH stimulation on top of an already-functional axis.

PCOS deserves special attention here. Women with PCOS often have elevated IGF-1 from insulin resistance-driven GH axis dysregulation. Adding CJC-1295 in a woman with uncontrolled PCOS and elevated IGF-1 could push IGF-1 above the normal range, potentially worsening androgen production and acne. The evidence is mechanistic rather than clinical trial-derived.

Perimenopause (Approximately Ages 45 to 52)

Erratic estrogen in perimenopause alters melanocortin receptor expression in ways that are not yet well characterized in humans. PT-141 use in perimenopause is off-label. GH and IGF-1 decline starts in earnest during this window, which is the most common stated rationale for CJC-1295 use among women in this life stage.

Sleep disruption in perimenopause already fragments the nighttime GH pulse, so pre-sleep CJC-1295 dosing attempts to partially restore what vasomotor symptoms interrupt. Whether this translates to meaningful changes in body composition in perimenopausal women has not been studied in a controlled trial.

Postmenopause

The Menopause Society (formerly NAMS) 2023 position statement does not address peptide therapies. Postmenopausal women are not represented in the PT-141 trial data and use is entirely off-label. Systemic estrogen loss removes a key modulator of melanocortin receptor density, which may reduce PT-141 efficacy, though this is inferred from animal models rather than human RCTs.

CJC-1295 is sometimes used in postmenopausal women on HRT. As noted above, transdermal estrogen preserves hepatic IGF-1 production better than oral estrogen, so the CJC-1295 response may be more strong in women using patches or gels than in those on oral estradiol.

Trying to Conceive and Fertility Considerations

Both peptides are contraindicated if you are trying to conceive. See the pregnancy section below.

Pregnancy, Lactation, and Contraception

This section is required reading if there is any chance you are or could become pregnant.

PT-141 (Bremelanotide) in Pregnancy

PT-141 is contraindicated in pregnancy. Animal reproductive studies show fetal harm at doses producing exposures similar to the clinical dose. No adequate human pregnancy data exist. The prescribing label explicitly states that Vyleesi should not be used during pregnancy and that healthcare providers should consider pregnancy testing before initiating therapy in women of reproductive potential. Reliable contraception is required during PT-141 use.

CJC-1295 in Pregnancy

CJC-1295 has no FDA pregnancy category because it is not an approved drug. No human pregnancy safety data exist. GH signaling is critical for placental function and fetal growth, and exogenous manipulation of the GHRH axis during pregnancy carries unknown risks. CJC-1295 should not be used during pregnancy or while trying to conceive.

Lactation

Neither PT-141 nor CJC-1295 has published human lactation transfer data. The FDA label for bremelanotide notes that the drug and its metabolites are present in rat milk, and recommends against use during breastfeeding. CJC-1295 has no lactation data at all. Both peptides should be considered incompatible with breastfeeding until proven otherwise.

Contraception Requirements

Any woman of reproductive age using PT-141 should use reliable contraception. Hormonal contraceptives are not known to interact with bremelanotide pharmacokinetics based on the prescribing label, but they may independently affect sexual desire, which complicates assessment of PT-141 effectiveness.

Who This Stack May Be Right For, and Who Should Avoid It

Potentially Appropriate

• Premenopausal women with diagnosed HSDD who have not responded to behavioral and psychological interventions alone, who also have a separate evidence-based reason to support GH-axis optimization (e.g., documented low IGF-1, significant body composition goals under clinical supervision)
• Women in perimenopause with both sexual desire concerns and documented GH decline, discussed with and monitored by a clinician familiar with peptide protocols
• Women who have already used one peptide as a single agent without adverse effects and want to add the second under medical supervision

Not Appropriate

• Pregnant women or women trying to conceive (contraindicated for both peptides)
• Breastfeeding women
• Women with uncontrolled hypertension: PT-141 raises systolic BP transiently and its prescribing label states it should not be used in women with cardiovascular disease or uncontrolled hypertension
• Women with active or history of hormone-sensitive cancers: CJC-1295 elevates IGF-1, and elevated IGF-1 has been associated with increased breast cancer risk in epidemiological studies, though causality is not established
• Women with uncontrolled PCOS and elevated baseline IGF-1
• Women who have not discussed the protocol with a licensed clinician: this stack involves at least one injectable prescription drug (bremelanotide) that legally requires a prescription in the United States

Side Effects: What to Watch for in Women

PT-141 Side Effects

In the Reconnect phase 3 trials, the most common adverse events in women were nausea (40.0% of the bremelanotide group vs. 1.3% of placebo), flushing (20.4%), and headache (11.0%). Nausea typically peaks within one hour of injection and resolves within two hours. Pre-treatment with an antiemetic (ondansetron 4 mg orally 30 to 60 minutes before) is used off-label by some practitioners to reduce this effect.

Transient hyperpigmentation (focal darkening at the injection site or on the face) has been reported with repeated PT-141 use and is a known class effect of melanocortin agonists.

CJC-1295 Side Effects

Reported effects in the published human study include injection-site reactions, headache, and flushing shortly after administration. With sustained IGF-1 elevation, carpal tunnel syndrome, fluid retention, and joint pain are possible, consistent with the known side-effect profile of GH excess. Insulin resistance is a theoretical concern with prolonged CJC-1295 use because GH is counter-regulatory to insulin; fasting glucose should be monitored.

Stacking-Specific Risk: Additive Flushing and Blood Pressure

Both peptides can cause flushing and transient cardiovascular effects. Administering them simultaneously would layer these side effects. Separating injections by at least 12 hours, as outlined in the timing protocol above, is the practitioner-recommended approach to reduce this overlap.

The Evidence Gap: What We Know and What We Don't

Women deserve a plain statement of what is proven versus extrapolated in this stack.

Directly studied in women via RCT:

• PT-141 at 1.75 mg for HSDD in premenopausal women (Reconnect trials, FDA-approved 2019)

Studied in humans but with limited or no female-specific data:

• CJC-1295 pharmacokinetics and GH response (the 2006 JClinEndocrinolMetab study included both sexes but did not stratify outcomes by sex)

Not studied in humans at all:

• This specific combination in any population
• PT-141 efficacy in postmenopausal women
• CJC-1295 in women with PCOS, perimenopause, or on HRT
• Long-term safety of either peptide beyond the trial periods (PT-141 trials were 24 weeks; CJC-1295 human data extend to only 56 days post-dose in the published pharmacokinetic study)

As stated in the 2019 FDA prescribing information for Vyleesi, "the long-term safety of bremelanotide has not been established." That statement was written for the single-agent drug. It applies with even more force to an unstudied combination.

WomanRx reviewer Dr. Maya Okafor, MD, notes: "When a patient asks me about stacking PT-141 with CJC-1295, my first question is always: have we addressed the underlying hormonal picture first? Low libido in a perimenopausal woman may respond to estrogen and testosterone optimization before we reach for peptides with less evidence. The stack is not dangerous if used carefully, but it is not a first-line answer either."

Regulatory and Legal Context

Bremelanotide (Vyleesi) is a Schedule V controlled substance in the United States and requires a prescription. Any compounded version labeled as "PT-141" for research use only is not approved for human administration, and purchasing such compounds outside a licensed pharmacy carries legal and safety risks, including unknown purity and concentration.

CJC-1295 is not a scheduled substance but is not FDA-approved for any human indication. The FDA has taken enforcement action against compounding pharmacies producing certain peptides outside of regulatory oversight. The legal field for peptide compounding in the United States is actively shifting as of 2025.